SPOTLIGHT -
Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast Cancer
Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.
Read More
A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical Practice
Sponsored Content by Tempus
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities
Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer
